Table 2.
Case | Age (years) |
Sex | Affected organs | Splenomegaly | Treatment | Efficacy of treatment | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 39 | M | Neuron, Lymph nodes | Mild | PSL | No change | ||||||
2 | 23 | M | Eye | Moderate | - | |||||||
3 | 74 | F | Skin | Mild | - | |||||||
4 | 69 | M | Neuron | - | PSL | No change | ||||||
5 | 40 | M | Eye | - | (PSL)* | No change | ||||||
6 | 41 | M | Lymph nodes | Marked | - | |||||||
7 | 44 | F | Eye | Mild | UDCA | Decreased liver enzymes | ||||||
8 | 49 | F | Heart, eye | - | ||||||||
9 | 71 | F | Eye | - | ||||||||
10 | 44 | M | Lung, eye | Mild | UDCA | No change | ||||||
11 | 70 | F | UDCA | Exacerbation | ||||||||
12 | 52 | M | Heart, Lung | PSL | Exacerbation | |||||||
13 | 41 | M | Eye, skin | Marked | PSL, UDCA | Exacerbation | ||||||
14 (Present case) |
22 | F | Lung, skin, spleen | Marked | Splenectomy | Favorable |
*PSL was administered to treat facial nerve palsy. PSL: prednisone, UDCA: ursodeoxycholic acid